SCHEMBL7299840

SCHEMBL7299840

O=C(O)/C=C/C(=O)OC(=O)c1ccccc1O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 6/20 0.51
HSD17B10 Q99714 4/20 0.51
ALOX15 P16050 1/20 0.51
TSHR P16473 2/20 0.50
LMNA P02545 1/20 0.50
KDM4E B2RXH2 5/20 0.47
ALDH1A1 P00352 3/20 0.47
TDP1 Q9NUW8 2/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
CA1 P00915 2/20 0.47
CA2 P00918 2/20 0.47
CA4 P22748 2/20 0.47
CA12 O43570 1/20 0.47
HMGB1 P09429 1/20 0.47
CA6 P23280 1/20 0.47
CA7 P43166 1/20 0.47
CA9 Q16790 1/20 0.47
NAPRT Q6XQN6 1/20 0.47
CA14 Q9ULX7 1/20 0.47
MAPT P10636 4/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6759172 0.92 LMNA (0.47) HPGDHSD17B10ALOX15TSHRLMNA
SCHEMBL6759171 0.92 LMNA (0.47) HPGDHSD17B10ALOX15TSHRLMNA
SCHEMBL33469 0.89 HCAR2 (0.50) HPGDHSD17B10ALOX15TSHRKDM4E
SCHEMBL8407382 0.82 MAPT (0.61) HPGDHSD17B10ALOX15LMNAKDM4E
SCHEMBL23357451 0.81 ALDH1A1 (0.51) HPGDHSD17B10TSHRKDM4EALDH1A1
SCHEMBL27571851 0.81 HCAR2 (0.41) HPGDHSD17B10ALOX15KDM4ESMN1; SMN2
Methyl Salicylate SCHEMBL27573598 0.81 TSHR (0.79) HPGDHSD17B10ALOX15TSHRLMNA
SCHEMBL28259523 0.80 ALDH1A1 (0.50) HPGDHSD17B10TSHRKDM4EALDH1A1
SCHEMBL240024 0.80 HSD17B10 (0.65) HPGDHSD17B10TSHRLMNAKDM4E
SCHEMBL28895697 0.80 CA12 (0.53) HPGDHSD17B10ALOX15KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3697775-A1 RET9 AND VEGFR2 INHIBITORS Kala Pharmaceuticals, Inc. (US) 2020-08-26 EP disclosed
WO-2019079747-A1 RET9 AND VEGFR2 INHIBITORS KALA PHARMACEUTICALS, INC. (US) 2019-04-25 WO disclosed
EP-0679084-A4 1995-11-08 EP disclosed
EP-0679084-A1 HYDANTOIN AND SUCCINIMIDE-SUBSTITUTED DERIVATIVES OF SPIROINDANYLCAMPHORSULFONYL OXYTOCIN ANTAGONISTS MERCK & CO. INC. (US) 1995-11-02 EP disclosed
WO-1994014438-A1 HYDANTOIN AND SUCCINIMIDE-SUBSTITUTED DERIVATIVES OF SPIROINDANYLCAMPHORSULFONYL OXYTOCIN ANTAGONISTS MERCK & CO., INC. (US) 1994-07-07 WO disclosed
US-5137904-A Useful in the treatment of atherosclerosis and thrombosis G. D. SEARLE & CO. (US) 1992-08-11 US disclosed
EP-0486280-A2 Piperidinylcamphorsulfonyl oxytocin antagonists MERCK & CO. INC. (US) 1992-05-20 EP disclosed
WO-1992007821-A1 DIASTEREOISOMERS OF BICYCLO-SUBSTITUTED PHENYLACETONITRILE DERIVATIVES G.D. SEARLE & CO. (US) 1992-05-14 WO disclosed